Form 144 - Report of proposed sale of securities:
SEC Accession No. 0000950170-25-036767
Filing Date
2025-03-10
Accepted
2025-03-10 21:40:49
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 2890
  Complete submission text file 0000950170-25-036767.txt   4394
Mailing Address C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLR. SOUTH SAN FRANCISCO Z4 94080
Business Address
Ali Faraz (Reporting) CIK: 0001667937 (see all company filings)

Type: 144

Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Subject) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-40656 | Film No.: 25725651
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)